Alivus Life Sciences: September-quarter EBITDA up 47% on a 41.8% margin, as Nirma sells 2.99% to Bandhan MF, Helios and Sanshi Fund (Mukul Agarwal) at ₹1,370

Alivus Life Sciences' September-quarter EBITDA rose 47% on a 41.8% margin. Eight days later, its promoter Nirma sold 2.99% of the company in two deals, and Bandhan Mutual Fund, Helios Mutual Fund and Sanshi Fund-I (Mukul Agarwal) were among the buyers of the main block. Is a stock at 52 times earnings still worth buying?

Alivus Life Sciences (NSE: ALIVUS, BSE: 543322), formerly Glenmark Life Sciences - Share price: ₹1,474 (11 November 2026, screener.in) - Market cap: ₹18,130 crore - P/E: 51.6 (trailing twelve months) - 52-week high / low: ₹1,574 / ₹819 - Closest listed peers: Divi's Laboratories 89.9x, Laurus Labs 99x

What happened on 6 November

Nirma Limited, Alivus's promoter, made two sales on 6 November:

- A block deal of 28.46 lakh shares (2.31% of the company) at ₹1,370 a share, worth about ₹390 crore - A bulk deal of 8.34 lakh shares (0.68%) at ₹1,422.29 a share, worth about ₹118.6 crore

Together that is about 36.8 lakh shares, 2.99% of the company and about ₹508 crore.

The buyers, as reported on the day:

Buyer Shares Amount --------- Bandhan Mutual Fund 8.56 lakh (across several schemes) about ₹117 crore Param Capital 7.29 lakh about ₹100 crore Setu Securities 4.10 lakh about ₹56 crore Subhkam Ventures I 2.50 lakh about ₹34 crore Helios Mutual Fund 2.18 lakh (two entries) about ₹30 crore Sanshi Fund-I (Mukul Agarwal) 2.00 lakh about ₹27 crore Norges Bank 1.83 lakh about ₹25 crore

Bandhan and Helios figures come from NSE bulk-deal data. The other quantities come from a news report and from exchange-derived deal records published by a data site. The seven quantities add up to the 28,46,300 shares sold in the block.

The block price was about 7.5% below the 6 November close of ₹1,480.60. Today's price is about 7.6% above the block price. Nirma held 74.85% at the end of September 2026. After both sales its stake is about 72% (74.85% minus 2.99%).

What to take from it A promoter selling 2.99% in one day, mostly at a discount is a supply event, not a verdict on the business. The names that bought, a mutual fund house, a Norwegian sovereign fund and an investor like Mukul Agarwal, show that professional money was willing to pay ₹1,370. They also had the discount to compensate them.

What Alivus does

Alivus makes active pharmaceutical ingredients (APIs), the part of a tablet that does the medical work. It sells them to drug companies in the US, Europe and Japan, and to emerging markets. Heart and nervous-system medicines together make about half of sales.

The company was incorporated on 23 June 2011 as Zorg Laboratories. Glenmark Pharmaceuticals bought it in July 2018 and renamed it Glenmark Life Sciences. Glenmark moved its API business into it on 1 January 2019, and the shares listed on NSE and BSE on 6 August 2021.

In September 2023 Nirma agreed to buy a 75% stake from Glenmark Pharmaceuticals at ₹615 a share, about ₹5,650 crore. The deal closed in March 2024 and made Nirma the promoter. The company has since changed its name to Alivus Life Sciences, and some exchange letters still use the old name.

It also runs a contract development and manufacturing business (CDMO), where drug companies pay it to design a chemical process and make the ingredient.

- Open-market business: about 79% of revenue, up about 21% from a year earlier - Captive supply to Glenmark Pharmaceuticals: about 21%, up 1% - CDMO: ₹50 crore in the September quarter, up about 80% in a year, about 7% of revenue - Ankleshwar plant: about 65% of revenue - Filings: more than 630 DMF and CEP filings (regulatory dossiers) worldwide

The September-quarter results

₹ crore Q2 FY27 Change on a year earlier --------- Revenue 682 +16% Gross profit 439 +29.5% EBITDA 285 +47% Net profit 197 (28.9% margin) margin up 680 basis points

₹ crore H1 FY27 Change on a year earlier --------- Revenue 1,322 +11.1% Gross profit 825 +22.9% EBITDA 519 +38.4% Net profit 357 (27% margin) margin up 590 basis points

EBITDA margin was 41.8% in the quarter, up 880 basis points. The company says about ₹24-25 crore of that was one-time income, a high-margin trial supply and a one-time customer item. Without it, the margin is about 39.5%. Gross margin was 64.4%, up 670 basis points.

Management gives two reasons for the better margins: - Mix: more sales from the open market and CDMO, which earn more than captive supply - New launches: complex molecules that sell at a premium for about 18 to 24 months before prices fall

Cash and balance sheet

- Cash and short-term investments: ₹1,012 crore at 30 September 2026 - Debt: the company says it is net debt-free - Free cash flow in H1: ₹270 crore, against net profit of ₹357 crore - Capex in H1: ₹190 crore (₹105 crore in Q2), for the Solapur plant and the Taloja research centre - Research spend in H1: ₹51 crore, 3.9% of sales

About three-quarters of the first-half profit turned into free cash flow, after a heavy capex quarter. Debtor days, payable days and the receivables figure were not in the sources used for this article, so they are not shown here.

What management says is next

These are the company's own forward-looking statements. They are not facts and not promises.

- FY27 revenue growth: 10-12% (reiterated) - FY27 EBITDA margin: 35-36% (reiterated) - FY27 captive supply to Glenmark: ₹700-750 crore - Open-market business: about ₹500 crore a quarter - FY28 EBITDA margin floor: 30-32% - CDMO: to double in 3-4 years, to 12-15% of revenue - Solapur plant, phase 1: starts in Q3 FY27 (October to December 2026); US FDA and EU GMP inspections within a year of that - Taloja research centre: early FY28 - High-potency APIs: 30 products in the active list, 14 validated, 7 in advanced development and 9 in the lab; sales window late FY28 to FY33-34; market size quoted by management at $86 billion - Flow chemistry: one project already in production with the cost of goods cut to less than half of the batch method; five more in 18 to 24 months - Pellet manufacturing: a partner facility is needed, 18 to 24 months away, for 15 developed pellet products - Acquisitions: the company is looking at more

H1 EBITDA margin is 39.3%, but the full-year guide is 35-36%. The CFO said the second half will bring more of the lower-margin captive supply, which pulls the blended margin down. A reader who values the stock on 40% margins is therefore ahead of the company's own guidance.

I did not compare past guidance with what the company later delivered in this article. Only the latest call was read in full. That check should be done before relying on the guidance above.

How the valuation compares

Company P/E (11 Nov 2026) Market cap (₹ crore) --------- Alivus Life Sciences 51.6 18,130 Divi's Laboratories 89.9 3,07,028 Laurus Labs 99.0 1,32,593 Sun Pharma 37.1 4,56,953 Zydus Lifesciences 26.8 1,21,286

Divi's and Laurus are the closest API and CDMO names, and both trade at much higher multiples. They are also far larger. Sun Pharma and Zydus sell finished medicines, so they are a weaker match. The peer set is the one shown by screener.in; the company's own annual report may list different peers.

Who owns the shares

Dec 2023 Sep 2024 Mar 2025 Sep 2025 Mar 2026 Sep 2026 --------------------- Promoters 82.85% 75.00% 74.99% 74.91% 74.87% 74.85% FIIs 4.57% 7.85% 6.57% 6.84% 5.30% 5.93% DIIs 0.74% 4.16% 5.19% 5.47% 7.27% 7.03%

The promoter line changed in 2024 when Nirma took over 75% from Glenmark Pharmaceuticals, which held about 83% before. It fell by about 7.9 points between December 2023 and September 2024. Domestic institutions (mutual funds and insurers) have grown from under 1% to about 7%. The shareholder count fell from about 1.86 lakh to about 1.23 lakh over the same period.

Other points from the filings

- On 18 August 2026 the board approved the purchase of a majority stake in IQGenX, a formulation research firm. No deal value was in the filing text read for this article.- A second acquisition was disclosed on 7 October 2026 with no target named in the text read. - A wholly owned subsidiary was set up in Brazil on 16 September 2026. No purpose or capital was stated. - 195,833 employee stock options were exercised by 29 October 2026. - On 11 November 2026 NSE asked the company about a spike in trading volume. The reply was pending at the time of writing.

Risks

- Margin shelf life: new-product margins fade after about 18 to 24 months, so the company must keep launching complex molecules. - Second-half squeeze: more captive supply in H2 will lower the blended margin from the Q2 peak. - One-time income: about ₹24-25 crore of Q2 EBITDA will not repeat. - Valuation: at 51.6 times trailing earnings, a miss on the 35-36% margin guide would hurt the share price. - Solvent prices: solvents are about 7-8% of the cost of goods and follow crude oil. - Promoter selling: Nirma sold 2.99% on one day, and more supply could come. - Disclosure gaps: two acquisitions with little detail and an open NSE query about volume.

So, what should an investor do?

The business case is real: open-market sales are growing at about 21%, the CDMO is scaling and the balance sheet holds ₹1,012 crore of cash. The question is price. The stock is about 7.6% above where large funds just bought, the company itself guides to lower margins than the first half showed, and it trades at 52 times earnings. A reader who wants to own it may prefer to wait for the NSE query to be answered and for the full-year margin to show up in the third-quarter results.

Note: I am not a SEBI-registered investment advisor. This article is for educational purposes only and is not investment advice. Please consult a registered financial advisor before making investment decisions.

Sources

- https://www.kotakneo.com/news/stocks/softbank-sells-lenskart-shares-and-alivus-promoter-offloads-stake/ - NSE bulk-deal data for 6 November 2026 (Bandhan Mutual Fund and Helios Mutual Fund entries in Alivus Life Sciences) - https://trendlyne.com/equity/bulk-block-deals/ALIVUS/606572/alivus-life-sciences-ltd - Alivus Life Sciences Q2 FY27 earnings call and results filings, 29 October 2026 (NSE announcements for ALIVUS) - NSE announcements for ALIVUS, 11 August to 11 November 2026